Firategrast for relapsing remitting multiple sclerosis: a phase 2, randomised, double-blind, placebo-controlled trial
David H. Miller(National Hospital for Neurology and Neurosurgery), Xavier Montalbán(Universitat de Vic - Universitat Central de Catalunya), Ole Graff(GlaxoSmithKline (Netherlands)), Gillian Atkinson(Research Triangle Park Foundation), Claire Wardell(GlaxoSmithKline (United Kingdom)), Joseph P. Horrigan, Tarek Yousry(National Hospital for Neurology and Neurosurgery), David MacManus(NIHR Queen Square Dementia Biomedical Research Unit), Thomas Weber(University Hospital in Halle), Richard Grove(GlaxoSmithKline (United Kingdom))
Cited by 77
Related Papers
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
|Annals of Neurology|2011|9.8k
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Defining the clinical course of multiple sclerosis
|Neurology|2014|3.1k
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
|New England Journal of Medicine|2010|2.2k
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
|New England Journal of Medicine|2016|2k